On the evening of June 1, Liu Jingqi, Deputy Director of Department of Science, Technology and International Cooperation of National Medical Products Administration, delivered a speech at a sub-forum of International Cooperation in Anti-Pandemic & the Path of High Quality Industrial Development, hosted by the Second Global Health Forum of Boao Forum for Asia.

Liu Jingqi, Deputy Director of Science and Technology and International Cooperation Department,  National Medical Products Administration 

Liu Jingqi said, since the outbreak of COVID-19, National Medical Products Administration has optimized the workflow, provided services and support for the research and clinical trials on a number of vaccines, drugs and medical devices with high efficiency, examined and approved a number of COVID-19 test kit and vaccines, tighten the quality supervision of the products on the market by emergency approval, and further improve the emergency review and approval system for drugs and medical devices. That the four vaccines have been approved for market use since December 31, 2020 demonstrates the emergency response capability of Chinese medical products administrations to deal with public health emergencies, and the contributions to promoting the health of all human beings by making Chinese vaccines as global public health products.

The global pandemic of the Covid-19 once again tells us that only countries around the world can work together to solve the common disaster facing mankind. Medicine regulatory departments in all countries should strengthen exchanges and cooperation, and work with the industry to build a health community for all mankind. National Medical Products Administration has long maintained good cooperation with the World Health Organization as well as other international organizations, and in recent years has actively participated in the work of International Coalition of Medicines Regulatory, International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use, APEC, Asian Harmonization Working Party and"One Belt, One Road" Initiative, promote the coordination of drug regulatory policies, establish and revise drug standards, accelerate the pace of convergence with international standards, and contribute to global drug regulatory work with Chinese wisdom and strength.

Liu Jingqi said that strong regulation promotes strong industry, and vice versa. We hope to promote the high-quality development of pharmaceutical industry by increasing regulatory capability building and policies, and we also expect the high-quality development of industry could improve the regulation level.

National Medical Products Administration is willing to work with all parties in society to ensure the safety of the public in the use of drugs and medical devices, to promote the high-quality development of the pharmaceutical industry, and to help China move toward a world leader in pharmaceutical.